Protein C as a surrogate end-point for clinical trials of sepsis

Identification of good surrogate end-points can greatly facilitate the design of clinical trials. Using data from PROWESS and ENHANCE, Shorr and colleagues explore the potential value of several plasma biomarkers for treatment trials of activated protein C for severe sepsis. Based on the framework p...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Kathleen D, Matthay, Michael A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447596/
https://www.ncbi.nlm.nih.gov/pubmed/18492215
http://dx.doi.org/10.1186/cc6859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447596/
https://www.ncbi.nlm.nih.gov/pubmed/18492215
http://dx.doi.org/10.1186/cc6859

Ejemplares similares